Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants

Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants
  • Soligenix Inc SNGX announced the results of a booster vaccination study using CiVax (heat-stable COVID-19 subunit vaccine program) in non-human primates (NHPs).
  •  The data demonstrated rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including against Delta and Omicron variants. 
  • The NHPs had been double vaccinated with an adenovirus vaccine for COVID-19 seven months previously. 
  • Before administering the booster vaccine, neutralizing antibody levels against the original and Delta strains were low but detectable and undetectable for the omicron strain. 
  • Within one week of receiving the booster, neutralizing antibody levels increased 27-fold against the original and Delta strains. By three weeks, this increased up to 243-fold. 
  • Protective neutralizing antibody levels were also rapidly raised against omicron by one-week post-vaccination.
  • Price Action: SNGX shares are up 0.99% at $0.69 during the market session on the last check Thursday.

Posted In: BriefsBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral